The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients' characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.

被引：0

作者：

Andre, Thierry

De Gramont, Aimery

Mineur, Laurent

Desrame, Jerome

Faroux, Roger

Bennouna, Jaafar

Dauba, Jerome

Louvet, Christophe

Pernot, Simon

Dupuis, Olivier Jean Marie

Becouarn, Yves

Mabro, May

Egreteau, Joelle

Bouche, Olivier

Bonnetain, Franck

de larauze, Marine Hug

Le Malicot, Karine

Taieb, Julien

机构：

[1] Hop St Antoine, F-75571 Paris, France

[2] Inst Hosp Franco Britann, Levallois Perret, France

[3] Inst St Catherine, Avignon, France

[4] Hop Prive Jean Mermoz, Lyon, France

[5] Ctr Hosp Dept Oudairies, La Roche Sur Yon, France

[6] Inst Cancerol Ouest, Nantes, France

[7] Ctr Hosp Layne, Mt De Marsan, France

[8] Inst Mutualiste Montsouris, Paris, France

[9] Hop Europeen Georges Pompidou, Paris, France

[10] Clin Victor Hugo, Le Mans, France

[11] Inst Bergonie, Bordeaux, France

[12] Hop Foch, Suresnes, France

[13] Ctr Hosp Bretagne Sud, Lorient, France

[14] Ctr Hosp Univ Robert Debre, Reims, France

[15] Ctr Hosp Reg & Univ, Besancon, France

[16] GERCOR, Paris, France

[17] FFCD, Dijon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 04期

关键词：

D O I：

10.1200/jco.2016.34.4_suppl.633

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

633

引用

页数：1

共 50 条

[21] Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
Takeshi Suto
Megumi Ishiguro
Chikuma Hamada
Katsuyuki Kunieda
Hiroyuki Masuko
Ken Kondo
Hideyuki Ishida
Genichi Nishimura
Kazuaki Sasaki
Takayuki Morita
Shoichi Hazama
Koutarou Maeda
Hideyuki Mishima
Hideyuki Ike
Sotaro Sadahiro
Kenichi Sugihara
Masazumi Okajima
Shigetoyo Saji
Junichi Sakamoto
Naohiro Tomita
International Journal of Clinical Oncology, 2017, 22 : 494 - 504
[22] Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
Suto, Takeshi
Ishiguro, Megumi
Hamada, Chikuma
Kunieda, Katsuyuki
Masuko, Hiroyuki
Kondo, Ken
Ishida, Hideyuki
Nishimura, Genichi
Sasaki, Kazuaki
Morita, Takayuki
Hazama, Shoichi
Maeda, Koutarou
Mishima, Hideyuki
Ike, Hideyuki
Sadahiro, Sotaro
Sugihara, Kenichi
Okajima, Masazumi
Saji, Shigetoyo
Sakamoto, Junichi
Tomita, Naohiro
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2017, 22 (03) : 494 - 504
[23] Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer
Iveson, Timothy J.
Sobrero, Alberto F.
Yoshino, Takayuki
Souglakos, Ioannis
Ou, Fang-Shu
Meyers, Jeffrey P.
Shi, Qian
Grothey, Axel
Saunders, Mark P.
Labianca, Roberto
Yamanaka, Takeharu
Boukovinas, Ioannis
Hollander, Niels H.
Galli, Fabio
Yamazaki, Kentaro
Georgoulias, Vassilis
Kerr, Rachel
Oki, Eiji
Lonardi, Sara
Harkin, Andrea
Rosati, Gerardo
Paul, James
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06) : 631 - +
[24] Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand
Lerdkiattikorn, Panattharin
Chaikledkaew, Usa
Lausoontornsiri, Wirote
Chindavijak, Somjin
Khuhaprema, Thirawud
Tantai, Narisa
Teerawattananon, Yot
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2015, 15 (04) : 687 - 700
[25] The use of adjuvant chemotherapy in patients with stage III colon cancer: A study of compliance with NIH recommendations
Jubelirer, S. J.
Gilliland, A.
Welch, C. A.
Emmett, M. K.
UICC WORLD CANCER CONGRESS, PROCEEDINGS, 2006, : 317 - +
[26] Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer
Kotaka, Masahito
Yamanaka, Takeharu
Yoshino, Takayuki
Manaka, Dai
Eto, Tetsuya
Hasegawa, Junichi
Takagane, Akinori
Nakamura, Masato
Kato, Takeshi
Munemoto, Yoshinori
Nakamura, Fumitaka
Bando, Hiroyuki
Taniguchi, Hiroki
Gamoh, Makio
Shiozawa, Manabu
Saji, Shigetoyo
Maehara, Yoshihiko
Mizushima, Tsunekazu
Ohtsu, Atsushi
Mori, Masaki
ESMO OPEN, 2018, 3 (03)
[27] Adjuvant chemotherapy for patients with stage III colon cancer, three months vs six months. A single centre experience
Martin-Montalvo, G.
Martinez Perez, D.
Ruiz-Gutierrez, I.
Alameda, M.
Rueda-Lara, A.
Pena, J.
Jimenez-Bou, D.
Vinal, D.
Garcia-Cuesta, J.
Pedregosa Barbas, J.
Rodriguez-Salas, N.
Feliu, J.
ANNALS OF ONCOLOGY, 2023, 34 : S114 - S114
[28] Erratum to: Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer
Takeshi Suto
Megumi Ishiguro
Chikuma Hamada
Katsuyuki Kunieda
Hiroyuki Masuko
Ken Kondo
Hideyuki Ishida
Genichi Nishimura
Kazuaki Sasaki
Takayuki Morita
Shoichi Hazama
Koutarou Maeda
Hideyuki Mishima
Hideyuki Ike
Sotaro Sadahiro
Kenichi Sugihara
Masazumi Okajima
Shigetoyo Saji
Junichi Sakamoto
Naohiro Tomita
International Journal of Clinical Oncology, 2017, 22 : 805 - 806
[29] CAPOX VERSUS MFOLFOX AS ADJUVANT CHEMOTHERAPY IN PATIENTS WITH STAGE 3 COLON CANCER: A COST-EFFECTIVENESS STUDY
Abuloha, S.
Li, P.
Bian, J.
Guo, Y.
Shao, H.
VALUE IN HEALTH, 2022, 25 (07) : S370 - S370
[30] A prospective study of the geriatric assessment in elderly stage III colorectal cancer patients on adjuvant chemotherapy
Okuno, Tatsuya
Tei, Mitsuyoshi
Yoshikawa, Yukihiro
Nomura, Masatoshi
Sueda, Toshinori
Matsumura, Tae
Miyagaki, Hiromichi
Tsujie, Masanori
Hasegawa, Junichi
Akamaru, Yusuke
ANNALS OF ONCOLOGY, 2022, 33 : S539 - S539

← 1 2 3 4 5 →